help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, T. J.
Right arrow Articles by Lea, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, T. J.
Right arrow Articles by Lea, R. G.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 12 4812-4817
Copyright © 2000 by The Endocrine Society


Original Studies

Human Fetal Testis: Second Trimester Proliferative and Steroidogenic Capacities1

Tessa J. Murray, Paul A. Fowler, David R. Abramovich, Neva Haites and Richard G. Lea

Nutrition and Development, The Rowett Research Institute (T.J.M., R.G.L.), Bucksburn, Aberdeen, Scotland AB21 9SB; and Departments of Obstetrics and Gynecology (T.J.M., P.A.F., D.R.A., R.G.L.) and Medical Genetics (N.H.), University of Aberdeen, Foresterhill, Aberdeen, Scotland AB25 2ZD

Address all correspondence and requests for reprints to: Dr. Richard G. Lea, Division of Maternal-Fetal Biology, The Rowett Research Institute, Greenburn Road, Bucksburn, Aberdeen, Scotland AB21 9SB. E-mail: rgl{at}rri.sari.ac.uk


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The period of Leydig cell hyperplasia (14–18 weeks gestation) in human fetal testis is crucial for normal gonad development. We have studied the spatio-temporal distribution of key developmental and functional markers in human fetal testis between 13–19 weeks gestation. Proliferating cell nuclear antigen-positive cells were immunolocalized to both interstitium and tubules. Image analysis confirmed an increase in positive interstitial cells during Leydig cell hyperplasia (P < 0.05). c-Myc was localized to the interstitium with no gestational changes. The steroidogenic enzymes 3ß-hydroxysteroid dehydrogenase (protein) and cytochrome P450 17{alpha}-hydroxylase/C17–20-lyase (P450c17; messenger ribonucleic acid and protein) were confined to the Leydig cells. The number of immunopositive cells increased between 13 and 19 weeks (P < 0.001). P450c17 mRNA (in situ hybridization) and protein were localized to the same population of interstitial Leydig cells. Androgen receptor and Bcl-2 protein (anti-apoptotic) were gradually restricted to the peritubular myoid cells as gestation progressed. Conversely, Bax protein (pro-apoptotic) was predominantly localized to the tubule Sertoli cells, whereas the germ cells were Bax immunonegative.

In conclusion, human fetal Leydig cell hyperplasia is characterized by increasing numbers of proliferating cells and increased expression of steroidogenic enzymes. The Bcl-2-positive, Bax-negative status of the peritubular myoid cells may be a strategy for cell survival.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
SEVERAL RECENT studies have linked decreasing male fertility with exposure to chemicals with hormonedisrupting activity (1, 2, 3, 4). In particular, animal models suggest that small endocrine changes induced by these chemicals may affect development of the fetal testis (5, 6, 7, 8, 9, 10). In the human, data in support of this hypothesis have been largely limited to epidemiological (11, 12, 13, 14, 15, 16, 17, 18, 19) and in vitro studies (20, 21). However, to elucidate the biological basis for these observations, it is essential to understand the processes that govern normal fetal testis development in the human.

In humans, the male gonad begins differentiation in the sixth week of gestation with the gradual development of testicular cords and interstitium from gonadal blastomas (22). Testicular cords are formed by the aggregation of Sertoli cells, and the germ cells are enclosed within these structures. The interstitial fetal Leydig cells begin differentiation during the eighth week of gestation (23) and undergo rapid proliferation until week 18, where upon a plateau is reached, and Leydig cell number remains at this level until the third trimester (24, 25). The period of Leydig cell hyperplasia is also coincident with a peak in fetal testosterone synthesis between 14 and 18 weeks gestation (23). Consequently, this period of Leydig cell hyperplasia is thought to be important in the development of the normal testis.

The balance among tissue growth, differentiation, and apoptosis is crucial for normal fetal gonad development (26, 27). To investigate the proliferative vs. apoptotic pathways in the human XY gonad between 13 and 19 weeks gestation, we used immunohistochemistry to localize expression of proliferating cell nuclear antigen (PCNA), c-Myc, Bcl-2, and Bax proteins. We have coordinated these expression profiles with the sequential differentiation of Leydig and peritubular myoid cells using markers for 3ß-hydroxysteroid dehydrogenase (3ß12HSD), cytochrome P450 17{alpha}-hydroxylase/C17–20-lyase (P450c17), and the androgen receptor (AR).


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Tissue collection and fixation

Ethical committee approval for the study was obtained from the Grampian Health Board and University of Aberdeen joint ethical committee (Project 2470), and tissue collection abided by the Polkinghorne committee recommendations for the use of human fetal material in research. Informed consent was obtained from women undergoing surgical termination of normally progressing second trimester pregnancies, and fetuses were collected between 13 and 19 weeks gestation. Testes were grouped according to gestational age as follows: 1) 13–14 weeks (n = 4), 2) 15–16 weeks (n = 4), 3) 17 weeks (n = 4), and 4) 18–19 weeks (n = 4). Testes were removed and immersion-fixed in Bouin’s solution for 5.5 h at 4 C, rinsed, and stored in 70% ethanol until routinely embedded in wax.

Immunohistochemistry

Sections (5 µm) were cut onto 3-aminopropyltriethoxysilane (Sigma, Poole, UK)-coated slides for the immunohistochemical localization of 1) PCNA; 2) protooncogene products c-myc, bcl-2, and bax; 3) steroidogenic enzymes P450c17 and 3ßHSD; and 4) AR. Commercially available antibodies were used for the detection of PCNA and AR (Novacastra Laboratories Ltd., Newcastle, UK), c-Myc and Bax (Santa Cruz Biotechnology, Inc., Heidelberg, Germany), and Bcl-2 (DAKO Corp., High Wycombe, UK). Antibodies for the detection of P450c17 and 3ßHSD were supplied by Prof. Ian Mason (University of Edinburgh, Edinburgh, UK).

Tissue sections were dewaxed in Histoclear (National Diagnostics, Hessel Hull, UK), rehydrated through a graded ethanol series, and washed in 0.1 mol/L Tris-buffered saline (pH 7.6) twice for 5 min each time. Pretreatment of the sections was necessary for localization of Bcl-2, Bax, 3ßHSD, P450c17, and AR (see below). Treatment with 3% hydrogen peroxide in water for 5 min at room temperature quenched endogenous peroxidase activity. All tissue sections were subjected to an endogenous biotin block using an avidin/biotin blocking kit (Vector Laboratories, Inc., Peterborough, UK) in accordance with the manufacturer’s protocol. This was followed by a nonimmune block using normal horse serum (Vector Laboratories, Inc.) for 20 min at room temperature. Tissues were then incubated with the appropriate primary antibody as follows: 1) immunolocalization of PCNA: monoclonal mouse anti-rat PCNA diluted 1:100 in normal horse serum for 60 min at room temperature; 2) immunolocalization of c-Myc: monoclonal mouse anti-human c-Myc at a dilution of 1:50 overnight at 4 C; 3) immunolocalization of Bcl-2: monoclonal mouse anti-human Bcl-2 at a dilution of 1:40 overnight at 4 C; 4) immunolocalization of Bax: polyclonal rabbit anti-human Bax at a dilution of 1:50 for 60 min at room temperature; and 5) immunolocalization of 3ßHSD and P450c17: rabbit anti-human 3ßHSD (type 1) and anti-pig P450c17 were both used after diluting 1:500, and tissue sections were incubated overnight at 4 C.

All tissue sections were labeled using an avidin-biotin-peroxidase detection system (Vector Laboratories, Inc.) followed by incubation with 3,3'-diaminobenzidine (DAB; Vector Laboratories, Inc.) for 5–15 min for brown color development. Finally, sections were counterstained with hematoxylin, dehydrated in graded ethanols, cleared in xylene, and coverslipped using Pertex mounting medium (Cellpath, Hemel Hempstead, UK). Negative controls were performed by replacing the primary antibody with normal mouse IgG at the same concentration.

Pretreatment of sections for Bcl-2, 3ßHSD, P450c17, and AR

To expose these epitopes, tissue sections were subjected to antigen retrieval by microwaving in 0.01 mol/L citrate buffer (pH 6.0) on full power twice for 5 min each time (Bax), three times for 5 min each time (Bcl-2), or four times for 5 min each time (3ßHSD, P450c17, and AR) and were allowed to stand for an additional 20 min.

Double immunostaining for AR and 3ßHSD, and PCNA and 3ßHSD

AR and 3ßHSD epitopes were exposed by microwaving three times for 5 min each time on full power and then were allowed to stand for an additional 20 min. Rabbit polyclonal anti-human AR was used after diluting 1:10, and tissue sections were incubated overnight at 4 C followed by biotinylated anti-rabbit IgG. The avidin-biotin-peroxidase labeling system was used and developed with DAB to produce a brown color on positive cells. After washing in Tris-buffered saline-Tween, the sections were incubated with the rabbit anti-3ßHSD antibody followed by biotinylated anti-rabbit IgG. The same labeling system was employed; however, Very Intense Purple (Vector Laboratories, Inc.) was used to develop the reaction, thereby generating a pink color. The following controls were carried out to ensure specific staining was observed 1) anti-AR was replaced by rabbit IgG before incubating with anti-3ßHSD; 2) anti-AR was followed by rabbit IgG in place of anti-3ßHSD; and 3) both primary antibodies were replaced with rabbit IgG. To ensure that staining could not be attributed to antibody cross-reactivity, the staining procedure was repeated with the primary antibodies switched.

Double immunostaining for PCNA and 3ßHSD was carried out using a similar protocol. As PCNA immunoreactivity is destroyed by microwaving, no antigen retrieval procedure was employed. Cells immunopositive for PCNA were detected using DAB as substrate, whereas 3ßHSD was visualized using Very Intense Purple. Specific staining was verified after running the controls described above, and antibody cross-reactivity was considered negligible after repeating the staining procedure with the primary antibodies switched over.

In situ hybridization for P450c17

Riboprobes for human P450c17. Human P450c17-pUC18 plasmid was provided by Prof. Stephen Hillier (University of Edinburgh, Edinburgh, UK). The plasmid was linearized with AccIII or BamHI for transcription with SP6 or T7 ribonucleic acid (RNA) polymerase to generate antisense and sense probes, respectively. Probes were radioactively labeled with 35S using a commercially available kit (Promega Corp. UK Ltd., Southampton, UK). Briefly, probes were incubated for 60 min at 37 C with 40 mmol/L Tris (pH 7.9), 6 mmol/L MgCl2, 2 mmol/L spermidine, 10 mmol/L NaCl, 10 mmol/L dithiothreitol (DTT), 40 U ribonuclease inhibitor, 1.85 MBq [35S]UTP (NEN Life Science Products, Boston, MA), and the appropriate RNA polymerase. After the addition of deoxyribonuclease, the probes were incubated at 37 C for an additional 30 min, after which purification was performed using RNA spin columns (Sigma).

In situ hybridization. In situ hybridization was carried out as previously described by Hoggard et al. (28) with a few minor modifications. Briefly, 5 µm sections cut over diethylpyrocarbonate (Sigma)-treated water and taken onto 3-aminopropyltriethoxysilane-coated slides were dewaxed with xylene and rehydrated through a decreasing ethanol series. Slides were immersed in 0.2 mol/L HCl for 20 min and then placed in 2 x SSC (1 x SSC contains 0.15 mol/L NaCl and 15 mmol/L sodium citrate, pH 7.0) for 30 min. Tissue sections were then treated with 2 µg/mL proteinase K (Sigma) in 0.2 mol/L Tris-HCl and 0.05 mol/L ethylenediamine tetraacetate (pH 7.6) for 20 min at 37 C, postfixed in 0.4% paraformaldehyde (Sigma) in phosphate-buffered saline for 20 min at 4 C, and washed in phosphate-buffered saline. Slides were acetylated with 0.25% acetic anhydride (Sigma) in 0.1 mol/L triethanolamine for 10 min before immersion in 2 x SSC and finally dehydration through graded ethanols, then air-dried.

Sections were hybridized with 106 cpm [35S]RNA in 60 µL hybridization buffer at 59 C overnight. Next day, sections were washed in 4 x SSC for 20 min, incubated in ribonuclease A (Sigma) solution (0.02 mg/mL in 0.01 mol/L Tris-HCl, 0.5 mol/L NaCl, and 0.1 mol/L ethylenediamine tetraacetate, pH 7.6) for 30 min at 37 C, and washed in 2 x SSC-DTT (SSC with 1 mmol/L DTT; Sigma). Slides were immersed in 1 x SSC-DDT for 10 min and in 0.5 x SSC-DTT for 10 min, then washed at 60 C with 0.1 x SSC-DTT before cooling in 0.1 x SSC. Sections were dehydrated in graded ethanols, air-dried, dipped in K5 nuclear emulsion (Ilford Ltd., Mobberley, UK), and exposed for 2 weeks at 4 C.

Slides were immersed in Phenisol developer (Ilford Ltd.) for 5 min, washed briefly, and fixed in Hypam fixing solution (Ilford Ltd.) for an additional 5 min. Slides were counterstained with Harris hematoxylin (Shandon International, Runcorn, UK) and examined by light microscopy.

Quantification and image analysis

For each marker, sections were visually scored on an arbitrary intensity scale by the same operator (T.M.). PCNA, c-Myc, 3ßHSD, and P450c17 were then selected to be quantified by computer-aided image analysis. The system was composed of an Olympus Corp. microscope (x20 objective; New Hyde Park, NY) and Hamamatsu digital camera (Hamamatsu, Bridgewater, NJ) connected to a computer running Image-Pro Plus software (Media Cybernetics, Silver Spring, MD). The tubular regions visible on captured images were digitally removed, and quantification was performed on the remaining interstitial tissue. The total area of positively stained cells (brown color) was measured and expressed as a percentage of the interstitial tissue area. In addition, PCNA staining within the tubules was quantified separately. Quantification was carried out over six randomly selected fields of view, after which the mean and SE had stabilized. Computer-aided image analysis was not performed for Bax, as no obvious changes were noted by visual scoring. Bcl-2 and AR showed an increase in staining intensity, but not area; therefore, quantification using digitized images was not possible.

Statistical analysis

Image analysis data were subjected to one-way ANOVA, and the Bonferroni/Dunn post-hoc test was used to compare values for PCNA, c-Myc, 3ßHSD, and P450c17 at different stages of gestation.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Immunolocalization of proliferation markers

In the human fetal testis, PCNA-immunopositive cells were detected in the tubules at all gestational ages examined (Fig. 1Go, a–c), possibly including the Sertoli population. PCNA immunostaining was also detected in the Leydig cellcontaining interstitial area between 15 and 17 weeks gestation (Fig. 1bGo); however, only low level immunostaining was observed at earlier (Fig. 1aGo) and later (Fig. 1cGo) gestational stages. Image analysis confirmed that the number of PCNA-immunopositive interstitial cells exhibited a significant increase from 13–14 weeks to 15–16 weeks gestation (by ANOVA, P < 0.05), followed by a significant decrease at 18–19 weeks (by ANOVA, P < 0.05; Fig. 2aGo). PCNA-positive cells within the tubules were consistently observed at a high level (Fig. 2aGo). c-Myc was exclusively localized to the cells in the interstitial area (Fig. 1mGo), and image analysis showed that expression levels did not change significantly between 13 and 19 weeks gestation (range expressed as the mean percent positive cells ± SEM, 36.88 ± 8.35 at 13–14 weeks, 43.07 ± 7.24 at 15–16 weeks; P > 0.05).



View larger version (149K):
[in this window]
[in a new window]
 
Figure 1. Immunolocalization of markers of cellular proliferation, apoptosis, and androgen action in the human fetal testis. The pattern of immunostaining of PCNA at 13–14 weeks (a), 15–16 weeks (b), and 18–19 weeks (c) shows that positive interstitial cells were most numerous at 15–16 weeks (arrows). Numerous PCNA-immunopositive cells were also noted in the tubules (T), possibly Sertoli cells. Immunostaining for Bax at 13–14 weeks (d), 15–16 weeks (e), and 18–19 weeks (f) shows that expression was predominately found in the tubular (T) regions of the gonad, although the germ cells were Bax negative (arrows). Bcl-2 immunostaining was interstitial and restricted to the PMCs (arrows) with advancing gestation (g–i; weeks as for Bax). Serial sections (relative to Bcl-2) double immunostained for 3ßHSD and AR showed 3ßHSD immunoreactivity in the interstitial Leydig cells (j–l; pink staining), and AR was localized to the PMCs (brown staining, arrows). c-Myc (m; 15–16 weeks) was constantly expressed by the interstitial cells (asterisks). P450c17 was immunolocalized to the Leydig cells (L) in the interstitium (n; 15–16 weeks). Double immunostaining (PCNA and 3ßHSD) showed the proliferating interstitial cells (o; 15–16 weeks; arrows; brown staining) to be immunonegative for 3ßHSD (asterisks; pink staining). Scale bar, 50 µm unless otherwise stated. Inset, IgG-negative control.

 


View larger version (15K):
[in this window]
[in a new window]
 
Figure 2. Changes in numbers of cells positive for PCNA-interstitium ({diamondsuit}), PCNA-tubules ({diamond}), 3ßHSD ({circ}), and P450c17 (•) in human fetal testis between 13 and 19 weeks gestation. Where common superscripts are shown above symbols, the values are significantly different (by ANOVA, P < 0.05) for each variable, not between variables. Values are expressed as the mean ± SEM (n = 4).

 
Immunolocalization of apoptosis markers

Bax was predominantly localized to the Sertoli cells within the tubules, although the germ cells were Bax immunonegative (Fig. 1Go, d–f). Light immunostaining was consistently observed in the interstitial area. Immunostaining intensity for Bax was independent of gestational age. Testicular cells immunopositive for Bcl-2 were detected in the interstitium and in the flattened peritubular myoid cells (PMCs) surrounding the tubules (Fig. 1Go, g–i). As gestation progressed from 13 to 19 weeks, the Bcl-2 immunostaining intensity markedly increased in PMCs, but decreased in the interstitial area. PMCs were notably Bax immunonegative while preserving high levels of Bcl-2.

Immunolocalization of 3ßHSD and P450c17

Immunostaining for 3ßHSD (Fig. 1Go, j–l) and P450c17 (Fig. 1nGo) allowed identification of the steroidogenically active Leydig cell population in the interstitial area. Subsequent image analysis showed the number of P450c17- and 3ßHSD-immunopositive cells in the interstitium significantly increased (by ANOVA, P < 0.001) over the period of investigation (Fig. 2bGo).

Double immunolocalization of AR and 3ßHSD: comparison with Bcl-2 immunostaining

AR was predominately expressed by the PMCs, with low level immunostaining in the interstitial area (Fig. 1Go, j–l). Conversely, 3ßHSD was specifically localized to the Leydig cell-containing interstitium. The expression profiles of 3ßHSD and AR are therefore markedly different. Examination of Bcl-2-immunostained serial sections revealed that AR and Bcl-2 were colocalized to the PMC population (Fig. 1Go, g—i, Bcl-2; Fig. 1Go, j—l, AR and 3ßHSD).

Double immunolocalization of PCNA and 3ßHSD

PCNA and 3ßHSD were immunolocalized to two distinct populations of interstitial cells. No double labeling was observed (Fig. 1oGo).

Expression of P450c17 messenger RNA (mRNA)

In situ hybridization using a 35S-labeled P450c17 complementary RNA probe resulted in hybridization in the interstitial area of the 13-week gestation testis (Fig. 3aGo). The silver grain clusters indicative of hybridization were more numerous in testis collected from later gestational stages (Fig. 3bGo). In all cases sense controls showed no signal above background levels (Fig. 3cGo). P450c17 mRNA and protein were therefore colocalized (Fig. 3Go, mRNA; Fig. 1nGo, protein).



View larger version (93K):
[in this window]
[in a new window]
 
Figure 3. Increase in P450c17 mRNA in human fetal testis between 13 and 19 weeks gestation using in situ hybridization with 35S-labeled complementary RNA to human P450c17. a, 13–14 weeks gestation; b, 18–19 weeks of gestation; c, sense control for 13–14 weeks gestation. Scale bar, 50 µm.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
This is the first study to localize markers of cellular proliferation, differentiation, and androgen action in testis from the human fetus. Computer-aided image analysis has provided objective quantification of key markers. We have shown that between 13 and 19 weeks gestation there are significant changes in the number of proliferating interstitial cells. This is coincident with the reported period of Leydig cell hyperplasia (23). Interstitial immunostaining for the protooncogene product c-Myc did not change significantly, although a trend similar to that for PCNA was observed. This period of gestation was also characterized by a steady increase in levels of the steroidogenic enzymes 3ßHSD and P450c17. In addition, the apoptosis regulatory factors Bcl-2 and Bax were localized to distinct cell populations. Of note, Bcl-2 was colocalized with AR in the peritubular myoid cells surrounding the tubules.

Although the Leydig population increased in number between 13 and 19 weeks, the proliferating interstitial cells were not steroidogenic. Furthermore, our data suggest that at the mRNA and protein levels, the increased steroid-secreting capacity of the fetal testis reflects increased numbers of Leydig cells rather than increased synthesis. This suggests that precursors of Leydig cells exist in the interstitial region before differentiation and that after undergoing a phase of rapid division they are recruited into the nonproliferative steroid-secreting population. This emphasizes the importance of proliferation of Leydig cell precursors to meet the steroidogenic requirements of the human fetal testis. In support of this, mature fetal Leydig cells have been shown to have no mitotic activity in the rat (29). In the human, however, proliferation of other interstitial cell types cannot be discounted.

Although proliferation was assessed through localization of PCNA and c-Myc, these markers had different temporal and spatial expression patterns during the gestational window examined. PCNA was detected in tubules where levels remained constant and consistently higher than those observed in the interstitial area from 13–19 weeks gestation. This supports previous studies that reported Sertoli cell proliferation during human and animal fetal life (30). The persistent interstitial expression of c-Myc may reflect its central role in the regulation of cellular growth and differentiation during this phase of rapid growth of the Leydig cells.

The balance between cell proliferation and cell death by apoptosis is critical during morphogenesis, and this is controlled in part through the expression of a large family of related apoptotic regulatory genes. The prototype apoptosis inhibitor is the protein product of the protooncogene bcl-2. The apoptosis-inhibiting effect of Bcl-2 occurs through homodimerization or heterodimerization with apoptosis- inducing factors such as Bax. Overexpression of Bax negates the protective mechanism of Bcl-2 and promotes apoptotic cell death (31). It follows, therefore, that the Bcl-2/Bax ratio is an important determinant of cell survival. The localization of Bax to Sertoli cells and the up-regulation of Bcl-2 in the interstitium along with consistent expression of c-Myc suggest that the competing pathways regulating the balance between proliferation and apoptosis favor expansion of the interstitium during this developmental period.

A critical observation in the current study was the colocalization of Bcl-2 and AR to the PMCs. These data indicate that the PMCs may play an important role during the development of the human fetal testis. Androgens are known to be important in the regulation of testicular apoptosis in the adult (32, 33) and may play a similar role in the fetus.

In adults the Sertoli cells are understood to be the main site for the action of androgens (34); however, adult human and rat PMCs and Leydig cells have also been reported to contain AR (35, 36). In contrast, in the fetal rat AR was specifically localized to the PMCs (37). In support of these studies, our data in the human fetal testis show that AR is also localized to PMCs, with no expression in Sertoli cells.

In contrast to that of PMCs, animal studies indicate that apoptotic cell death of fetal germ cells is a normal feature of testis development late in gestation (27, 38). Germ cell apoptosis also occurs in adult rats and mice, and this is thought to account for the 25–75% loss of the expected sperm yield during normal spermatogenesis (27). In the human fetal testis Bax was localized to the tubules, although the germ cells were notably Bax immunonegative. As the germ cell Bcl-2/Bax ratio is not in favor of apoptosis, germ cell death may not occur from 13–19 weeks gestation in the human. However, other apoptotic regulatory genes may be involved, and confirmatory studies are necessary to localize cells with fragmented DNA in human fetal testis.

In conclusion, the period of Leydig cell hyperplasia in human fetal testis has been characterized by 1) a transient, but significant, increase in the number of proliferating cells and 2) a significant increase in the number of interstitial cells expressing the steroidogenic enzymes 3ßHSD and P450c17. The proliferating interstitial cells were not immunopositive for 3ßHSD and are therefore probably Leydig cell precursors. AR and Bcl-2 proteins were gradually restricted to the peritubular myoid cells as gestation progressed from 13 to 19 weeks, and the predominance of Bcl-2 may be a strategy for survival of this cell population. In contrast, Bax was mainly localized to the tubules, although the germ cells were negative. These studies suggest that the regulation of apoptosis and cell proliferation in the developing human fetal testis is critical for steroidogenesis, steroid action, and normal male development.


    Acknowledgments
 
We sincerely thank Prof. J. I. Mason for the donation of 3ßHSD antibody and P450c17 antibody, and Prof. S. G. Hillier for providing P450c17 plasmid.


    Footnotes
 
1 This work was supported by the James Alexander Mearns Trust (to P.A.F., D.R.A., N.H., and R.G.L.). Back

Received December 16, 1999.

Revised May 22, 2000.

Revised August 29, 2000.

Accepted September 2, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Sharpe RM. 1993 Declining sperm counts in men: is there an endocrine cause? J Endocrinol. 136:357–360.[Abstract/Free Full Text]
  2. Sharpe RM, Skakkebaek NE. 1993 Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet. 341:1392–1395.[CrossRef][Medline]
  3. Jensen TK, Toppari J, Keiding N, Skakkebaek NE. 1995 Do environmental estrogens contribute to the decline in male reproductive health? Clin Chem. 41:1896–1901.[Abstract/Free Full Text]
  4. Toppari J, Larsen JC, Christiansen P, et al. 1996 Male reproductive health and environmental xenoestrogens. Environ Health Perspect. 104(Suppl 4):741–803.
  5. Sharpe RM, Fisher JS, Millar MM, Jobling S, Sumpter JP. 1995 Gestational and lactational exposure of rats to xenoestrogens results in reduced testicular size and sperm production. Environ Health Perspect. 103:1136–1143.[Medline]
  6. Majdic G, Sharpe RM, O’Shaughnessy PJ, Saunders PT. 1996 Expression of cytochrome P450 17{alpha}-hydroxylase/C17–20 lyase in the fetal rat testis is reduced by maternal exposure to exogenous estrogens. Endocrinology. 137:1063–1070.[Abstract]
  7. Majdic G, Sharpe RM, Saunders PT. 1997 Maternal oestrogen/xenoestrogen exposure alters expression of steroidogenic factor-1 (SF-1/Ad4BP) in the fetal rat testis. Mol Cell Endocrinol. 127:91–98.[CrossRef][Medline]
  8. Sweeney T, Brooks AN, Roche JF. 1998 Exposure to xenoestrogens in-utero suppresses FSH, testis size and Sertoli cell number in the new-born lamb. J Reprod Fertil Abstr Ser. 21:35.
  9. vom Saal FS, Cooke PS, Buchanan DL, et al. 1998 A physiologically based approach to the study of bisphenol A and other estrogenic chemicals on the size of reproductive organs, daily sperm production, and behavior. Toxicol Ind Health. 14:239–260.[Medline]
  10. Gray Jr LE, Wolf C, Lambright C, et al. 1999 Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p'-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicol Ind Health. 15:94–118.[Abstract/Free Full Text]
  11. Bostofte E, Serup J, Rebbe H. 1983 Has the fertility of Danish men declined through the years in terms of semen quality? A comparison of semen qualities between 1952 and 1972. Int J Fertil. 28:91–95.[Medline]
  12. Bendvold E. 1989 Semen quality in Norwegian men over a 20-year period. Int J Fertil. 34:401–404.[Medline]
  13. Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. 1992 Evidence for decreasing quality of semen during past 50 years. Br Med J. 305:609–613.
  14. Auger J, Kunstmann JM, Czyglik F, Jouannet P. 1995 Decline in semen quality among fertile men in Paris during the past 20 years. N Engl J Med. 332:281–285.[Abstract/Free Full Text]
  15. Adamopoulos DA, Pappa A, Nicopoulou S, et al. 1996 Seminal volume and total sperm number trends in men attending subfertility clinics in the greater Athens area during the period 1977–1993. Hum Reprod. 11:1936–1941.[Abstract/Free Full Text]
  16. Irvine S, Cawood E, Richardson D, MacDonald E, Aitken J. 1996 Evidence of deteriorating semen quality in the United Kingdom: birth cohort study in 577 men in Scotland over 11 years. Br Med J. 312:467–471.[Abstract/Free Full Text]
  17. Joffe M. 1996 Decreased fertility in Britain compared with Finland. Lancet. 347:1519–1522.[CrossRef][Medline]
  18. Van Waeleghem K, De Clercq N, Vermeulen L, Schoonjans F, Comhaire F. 1996 Deterioration of sperm quality in young healthy Belgian men. Hum Reprod. 11:325–329.
  19. Andersen AG, Jensen TK, Carlsen E, et al. 2000 High frequency of sub-optimal semen quality in an unselected population of young men. Hum Reprod. 15:366–372.[Abstract/Free Full Text]
  20. Brown E, Abramovich DR, Wallace HM, et al. 1998 Testosterone and inhibin B secretion by human fetal testicular explants are suppressed by in vitro exposure to the environmental toxicant dieldrin. J Reprod Fertil Abstr Ser. 21:26.
  21. Murray TJ, Fowler PA, Abramovich DR, Haites NE, Lea RG. 1999 Proliferation and apoptosis in the developing human fetal testis: possible effects of endocrine disrupting chemicals (EDCs). J Reprod Fertil Abstr Ser. 24:14.
  22. Gondos B. 1980 Development and differentiation of the testis and male reproductive tract. In: Steinberger A, Steinberger E, eds. Testicular development, structure, and function. New York: Raven Press; 3–20.
  23. Voutilainen R. 1992 Differentiation of the fetal gonad. Horm Res. 38:66–71.
  24. Niemi M, Ikonen M, Hervonen A. 1967 Histochemistry and fine structure of the intersitial tissue in the human foetal testis. In: Wolstanholme GEW, O’Connor M, eds. Ciba Foundation colloquia on endocrinology: endocrinology of the testis. London, Churchill; 31–55.
  25. Codesal J, Regadera J, Nistal M, Regadera-Sejas J, Paniagua R. 1990 Involution of human fetal Leydig cells. An immunohistochemical, ultrastructural and quantitative study. J Anat. 172:103–114.[Medline]
  26. Haanen C, Vermes I. 1996 Apoptosis: programmed cell death in fetal development. Eur J Obstet Gynecol Reprod Biol. 64:129–133.[CrossRef][Medline]
  27. Wang RA, Nakane PK, Koji T. 1998 Autonomous cell death of mouse male germ cells during fetal and postnatal period. Biol Reprod. 58:1250–1256.[Abstract/Free Full Text]
  28. Hoggard N, Hunter L, Duncan JS, Williams LM, Trayhurn P, Mercer JG. 1997 Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta. Proc Natl Acad Sci USA. 94:11073–11078.[Abstract/Free Full Text]
  29. Orth JM. 1982 Proliferation of Sertoli cells in fetal and postnatal rats: a quantitative autoradiographic study. Anat Rec. 203:485–492.[CrossRef][Medline]
  30. Cortes D, Muller J, Skakkebaek NE. 1987 Proliferation of Sertoli cells during development of the human testis assessed by stereological methods. Int J Androl. 10:589–596.[Medline]
  31. Oltvai ZN, Milliman CL, Korsmeyer SJ. 1993 Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–619.[CrossRef][Medline]
  32. Erkkila K, Henriksen K, Hirvonen V, et al. 1997 Testosterone regulates apoptosis in adult human seminiferous tubules in vitro. J Clin Endocrinol Metab. 82:2314–2321.[Abstract/Free Full Text]
  33. Woolveridge I, Bryden AA, Taylor MF, George NJ, Wu FC, Morris ID. 1998 Apoptosis and expression of apoptotic regulators in the human testis following short- and long-term anti-androgen treatment. Mol Hum Reprod. 4:701–707.[Abstract/Free Full Text]
  34. Sharpe RM. 1994 Regulation of spermatogenesis. In: Knobil E, Neill JD, eds. The physiology of reproduction. New York: Raven Press; 1363–1434.
  35. Suarez-Quian CA, Martinez-Garcia F, Nistal M, Regadera J. 1999 Androgen receptor distribution in adult human testis. J Clin Endocrinol Metab. 84:350–358.[Abstract/Free Full Text]
  36. Bremner WJ, Millar MR, Sharpe RM, Saunders PT. 1994 Immunohistochemical localization of androgen receptors in the rat testis: evidence for stage-dependent expression and regulation by androgens. Endocrinology. 135:1227–1234.[Abstract]
  37. Majdic G, Millar MR, Saunders PT. 1995 Immunolocalisation of androgen receptor to interstitial cells in fetal rat testes and to mesenchymal and epithelial cells of associated ducts. J Endocrinol. 147:285–293.[Abstract/Free Full Text]
  38. Coucouvanis EC, Sherwood SW, Carswell-Crumpton C, Spack EG, Jones PP. 1993 Evidence that the mechanism of prenatal germ cell death in the mouse is apoptosis. Exp Cell Res. 209:238–247.[CrossRef][Medline]



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
P. A. Fowler, S. Cassie, S. M. Rhind, M. J. Brewer, J. M. Collinson, R. G. Lea, P. J. Baker, S. Bhattacharya, and P. J. O'Shaughnessy
Maternal Smoking during Pregnancy Specifically Reduces Human Fetal Desert Hedgehog Gene Expression during Testis Development
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 619 - 626.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. J. O'Shaughnessy, P. J. Baker, A. Monteiro, S. Cassie, S. Bhattacharya, and P. A. Fowler
Developmental Changes in Human Fetal Testicular Cell Numbers and Messenger Ribonucleic Acid Levels during the Second Trimester
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4792 - 4801.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P. A. Fowler, D. R. Abramovich, N. E. Haites, P. Cash, N. P. Groome, A. Al-Qahtani, T. J. Murray, and R. G. Lea
Human fetal testis Leydig cell disruption by exposure to the pesticide dieldrin at low concentrations
Hum. Reprod., November 1, 2007; 22(11): 2919 - 2927.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Boukari, M. L. Ciampi, A. Guiochon-Mantel, J. Young, M. Lombes, and G. Meduri
Human fetal testis: source of estrogen and target of estrogen action
Hum. Reprod., July 1, 2007; 22(7): 1885 - 1892.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. M. Naciff, K. A. Hess, G. J. Overmann, S. M. Torontali, G. J. Carr, J. P. Tiesman, L. M. Foertsch, B. D. Richardson, J. E. Martinez, and G. P. Daston
Gene Expression Changes Induced in the Testis by Transplacental Exposure to High and Low Doses of 17{alpha}-Ethynyl Estradiol, Genistein, or Bisphenol A
Toxicol. Sci., August 1, 2005; 86(2): 396 - 416.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
T. L. Gaskell, A. Esnal, L. L.L. Robinson, R. A. Anderson, and P. T.K. Saunders
Immunohistochemical Profiling of Germ Cells Within the Human Fetal Testis: Identification of Three Subpopulations
Biol Reprod, December 1, 2004; 71(6): 2012 - 2021.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
E. D. Albrecht, R. B. Billiar, G. W. Aberdeen, J. S. Babischkin, and G. J. Pepe
Expression of Estrogen Receptors {alpha} and {beta} in the Fetal Baboon Testisand Epididymis
Biol Reprod, April 1, 2004; 70(4): 1106 - 1113.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. L. L. Robinson, J. Townsend, and R. A. Anderson
The Human Fetal Testis Is a Site of Expression of Neurotrophins and Their Receptors: Regulation of the Germ Cell and Peritubular Cell Population
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3943 - 3951.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
I. Ketola, J. Toppari, T. Vaskivuo, R. Herva, J. S. Tapanainen, and M. Heikinheimo
Transcription Factor GATA-6, Cell Proliferation, Apoptosis, and Apoptosis-Related Proteins Bcl-2 and Bax in Human Fetal Testis
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1858 - 1865.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
I. A. Hughes
Minireview: Sex Differentiation
Endocrinology, August 1, 2001; 142(8): 3281 - 3287.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, T. J.
Right arrow Articles by Lea, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, T. J.
Right arrow Articles by Lea, R. G.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals